GS-EU-131-0247 A Phase 3, Double-Blind, Multicenter, Randomized,Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)
(akute lymphatische Leukämie, ALL, Leukämie, Blutkrebs, weiße Blutkörperchen, Blut, blutbildendes System, Leukozyten, Lymphoblasten)